$TLX News

Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target

Telix Reports Third Quarter 2026 Financial Performance

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

Ekalia takes an important step in the deployment of Astatine-211 in the United States through a collaboration agreement with Telix

Telix And Ekalia, IBA-Framatome Joint Venture, Collaborate On US Astatine-211 Production, Securing Priority Isotope Access For TLX102-Tx Glioblastoma Pipeline

Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM

Telix to Host Capital Markets Day in Melbourne on November 4, 2026

Telix Pharmaceuticals: Merger Bodes Well For Long-Term Plan

First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

Telix Pharmaceuticals Says First Patients In US Dosed With Pixclara, FDA-Approved, Amino Acid Positron Emission Tomography Drug For Glioma Imaging

Wall Street Analysts Believe Telix Pharmaceuticals Limited (TLX) Could Rally 83.42%: Here's is How to Trade

Telix Receives FDA's Fast Track Designation For Its BiPASS Program To Trace Prostate Cancer Prior To Biopsy

Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging

HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target

Telix (ASX:TLX) Shares Could Be 42% Undervalued Following Its ITM Deal

Telix Pharmaceuticals (ASX:TLX) ITM Deal Puts Valuation Back In Focus

Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target

Telix (TLX) to Buy Germany’s ITM for up to $2.35 Billion to Lock in its Cancer Isotope Supply

Telix Pharmaceuticals (ASX:TLX) Lands $2.35 Billion Deal To Reshape Radiopharmaceutical Reach